PFIZER INCPFE
時価総額
$1423.6億
PER
研究開発型グローバルバイオ医薬品の最大手（1942年6月設立）。ワクチンや医薬品（Comirnaty、Paxlovid等）を展開。2022年にBiohavenを約118億ドルで買収、同年にArenaを約66億ドルで買収。約200カ国・地域に供給。
| 2010年 12月31日 | 2011年 12月31日 | 2012年 12月31日 | 2013年 12月31日 | 2014年 12月31日 | 2015年 12月31日 | 2016年 12月31日 | 2017年 12月31日 | 2018年 12月31日 | 2019年 12月31日 | 2020年 12月31日 | 2021年 12月31日 | 2022年 12月31日 | 2023年 12月31日 | 2024年 12月31日 | |
| Product | - | - | - | - | - | - | - | - | - | 664 | 284 | 590 | - | - | 53,816 |
| Royalty | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1,423 |
| Revenues | 67,809 | 67,425 | 58,986 | 51,584 | 49,605 | 48,851 | 52,824 | 52,546 | 53,647 | 51,750 | 41,908 | 81,288 | 100,330 | 58,496 | 63,627 |
| Alliance revenues | - | - | - | - | - | - | - | - | - | - | - | - | - | 7,582 | 8,388 |
| Cost of sales | 16,279 | 15,085 | 11,334 | 9,586 | - | - | - | - | 11,248 | 10,219 | 8,692 | 30,821 | 34,344 | 24,954 | 17,851 |
| Selling, General and Administrative Expense | 19,614 | 19,468 | 16,616 | 14,355 | 14,097 | 14,809 | 14,837 | 14,784 | 14,455 | 14,350 | 11,615 | 12,703 | 13,677 | 14,771 | 14,730 |
| Research and development expenses | 9,413 | 9,112 | 7,870 | 6,678 | 8,393 | 7,690 | 7,872 | 7,657 | 8,006 | 8,650 | 9,405 | 13,829 | 11,428 | 10,679 | 10,822 |
| Acquired in-process research and development expenses | - | - | - | - | - | - | - | - | - | - | - | - | 953 | 194 | 108 |
| Amortization of intangible assets | - | - | 5,175 | 4,599 | 4,039 | 3,728 | 4,056 | 4,758 | 4,893 | 4,610 | 3,436 | 3,700 | 3,609 | 4,733 | 5,286 |
| Restructuring Charges And Acquisition Related Costs | 3,214 | 2,934 | 1,880 | 1,182 | 250 | 1,152 | 1,724 | 487 | 1,044 | 747 | 600 | 802 | 1,375 | 2,943 | 2,419 |
| Other (income)/deductions––net | - | - | - | - | -1,009 | -2,860 | -3,655 | -1,315 | -2,116 | -3,578 | -669 | 4,878 | -217 | 835 | -4,388 |
| Income from continuing operations before provision/(benefit) for taxes on income | - | 12,762 | 12,080 | 15,716 | 12,240 | 8,965 | 8,351 | 12,305 | 11,885 | 17,682 | 7,497 | 24,311 | 34,729 | 1,058 | 8,023 |
| Income Tax Expense (Benefit) | 1,124 | 4,023 | 2,562 | 4,306 | 3,120 | 1,990 | 1,123 | -9,049 | 706 | 1,384 | 477 | 1,852 | 3,328 | -1,100 | -28 |
| Income from continuing operations | 8,298 | 8,739 | 9,518 | 11,410 | 9,119 | 6,975 | 7,229 | 21,353 | 11,179 | 16,298 | 7,021 | 22,459 | 31,401 | 2,172 | 8,051 |
| Discontinued operations––net of tax | -9 | 1,312 | 5,080 | 10,662 | 48 | 11 | 17 | 2 | 10 | 4 | 2,631 | -434 | 6 | -15 | 11 |
| Net income before allocation to noncontrolling interests | 8,289 | 10,051 | 14,598 | 22,072 | 9,168 | 6,986 | 7,246 | 21,355 | 11,188 | 16,302 | 9,652 | 22,025 | 31,407 | 2,158 | 8,062 |
| Less: Net income attributable to noncontrolling interests | 32 | 42 | 28 | 69 | 32 | 26 | 31 | 47 | 36 | 29 | 36 | 45 | 35 | 39 | 31 |
| Net income attributable to Pfizer Inc. common shareholders | 8,289 | 10,051 | 14,598 | 22,072 | 9,168 | 6,986 | 7,246 | 21,355 | 11,188 | 16,302 | 9,652 | 22,025 | 31,407 | 2,158 | 8,062 |
| Income (Loss) from Continuing Operations, Per Basic Share | 1.03 | 1.11 | 1.27 | 1.67 | 1.43 | 1.13 | 1.18 | 3.57 | 1.9 | 2.92 | 1.26 | 4 | 5.59 | 0.38 | 1.42 |
| Discontinued operations––net of tax (in dollars per share) | - | 0.17 | 0.68 | 1.56 | 0.01 | - | - | - | - | - | 0.47 | -0.08 | - | - | - |
| Net income attributable to Pfizer Inc. common shareholders (in dollars per share) | 1.03 | 1.28 | 1.96 | 3.23 | 1.44 | 1.13 | 1.18 | 3.57 | 1.9 | 2.92 | 1.73 | 3.92 | 5.59 | 0.38 | 1.42 |
| Income (Loss) from Continuing Operations, Per Diluted Share | 1.02 | 1.11 | 1.26 | 1.65 | 1.41 | 1.11 | 1.17 | 3.52 | 1.86 | 2.87 | 1.24 | 3.93 | 5.47 | 0.37 | 1.41 |
| Discontinued operations––net of tax (in dollars per share) | - | 0.17 | 0.68 | 1.54 | 0.01 | - | - | - | - | - | 0.47 | -0.08 | - | - | - |
| Net income attributable to Pfizer Inc. common shareholders (in dollars per share) | 1.02 | 1.27 | 1.94 | 3.19 | 1.42 | 1.11 | 1.17 | 3.52 | 1.87 | 2.87 | 1.71 | 3.85 | 5.47 | 0.37 | 1.41 |